Recent clinical trials indicate that cannabidiol (CBD) may reduce seizure frequency in pediatric patients with certain forms of treatment-resistant epilepsy. Many of these patients experience significant impairments in quality of life (QOL) in physical, mental, and social dimensions of health. In this study, we measured the caregiver-reported Quality of Life in Childhood Epilepsy (QOLCE) in a subset of patients enrolled in a prospective, open-label clinical study of CBD. Results from caregivers of 48 patients indicated an 8.2 AE 9.9-point improvement in overall patient QOLCE (p < 0.001) following 12 weeks of CBD. Subscores with improvement included energy/fatigue, memory, control/helplessness, other cognitive functions, social interactions, behavior, and global QOL. These differences were not correlated to changes in seizure frequency or adverse events. The results suggest that CBD may have beneficial effects on patient QOL, distinct from its seizurereducing effects; however, further studies in placebo-controlled, double-blind trials are necessary to confirm this finding.
Children with chronic epilepsy experience significant impairments in physical, mental, and social domains of quality of life (QOL) as reported by patients or parents. 1, 2 Epilepsy-specific QOL questionnaires can evaluate the effects of seizures and antiepileptic medications (AEDs), 3, 4 supplementing assessment by physicians who often fail to address under-reported symptoms and/or do not directly address physical, psychosocial, and occupational/educational effects of epilepsy and therapies. 5 Epilepsy can contribute to low self-esteem, anxiety, depression, impaired memory and attention, lack of independence, and social stigma. 1, 2, 6 The Quality of Life in Childhood Epilepsy (QOLCE) survey measures multiple QOL domains in different populations, with good response rates, internal consistency, and test-retest reliability. 1, 2, 7, 8 An open-label trial 9 suggested that CBD can reduce seizure frequency in children and young adults with treatmentresistant epilepsy; three randomized, placebo-controlled phase III trials have been completed in Dravet and LennoxGastaut syndromes (NCT02091375, NCT02224560, NCT02224560), and preliminary reports support efficacy in both syndromes. 10 Parents of children with severe epilepsies treated with vernacular CBD preparations reported improved mood, behavior, language, alertness, motor skills, and sleep, but also drowsiness, fatigue, and reduced appetite. 6, 11 A phase II expanded access program (EAP) study found CBD was generally well tolerated; common adverse events included somnolence (25%), decreased appetite (19%), diarrhea (19%), fatigue (13%), and convulsions (11%). 9 Here, we directly examine the change in QOLCE in patients before and after 12 weeks of CBD treatment.
Methods

Study background and design
Patients enrolled in a prospective, physician-sponsored, open-label EAP at the New York University (NYU) Epilepsy Center between January 15, 2014, and April 15, 2015, to measure potential seizure-reducing properties of purified CBD (Epidiolex; GW Pharmaceuticals, United Kingdom). These subjects included a subset of those previously described 9 and subjects enrolled after the reported cutoff date. Patients were aged 1-30 years and had intractable childhood onset epilepsy with four or more countable seizures with a motor component per 4-week period. We excluded patients with baseline liver, renal, or hematological laboratory abnormalities, or initiation of felbamate or vigabatrin within 6 months before enrollment. Patients with progressive disorders were excluded. The NYU Langone Medical Center Institutional Review Board approved the study, and written informed consent was obtained from the subjects or legally authorized representatives.
After enrollment, parents/patients kept a diary over a 4-week pre-CBD baseline period during which patients were on stable doses of AEDs, dietary therapy, and/or stable vagus nerve stimulator settings. Seizure diaries reported seizures with a sustained (>3 s) motor component (motor seizures), including tonic-clonic, tonic, clonic, atonic, and focal seizures with prominent motor features. Patients received a 99% oil-based CBD extract of constant composition in a 100-mg/mL sesame oil-based solution administered orally or by gastric tube. CBD (2-5 mg/kg/day divided in twice-daily dosing) was added to the baseline AEDs, then titrated (2-5 mg/kg/week until intolerance or maximum dose of 50 mg/kg/day). Background AEDs and vagus nerve stimulation settings were kept stable during the 12-week observation period. Single dose reductions in background AEDs were permitted if the investigator felt there was worsening sedation (attributed to pharmacokinetic or pharmacodynamic interactions with CBD); no new medications were started.
QOL assessment
Caregivers completed the U.S. version of the QOLCE survey 12 at the pretreatment visit and after 12 weeks of treatment. The questionnaire assessed 91 items, most of them subdivided into five domains: physical function (12 items, including physical restrictions and energy/fatigue subscales), cognitive function (23 items), emotional wellbeing (19 items), social function (12 items), and behavior (23 items). The QOLCE also measured general health compared to children of the same age and overall QOL. Responses were scored on a five-point Likert scale, and subscore values were linearly converted to a 100-point scale. 8 Overall QOL was computed by obtaining the sum of the subscores and dividing by 16. Mean imputation using the group's question responses at the same time point (baseline or post-CBD) was performed for individual missing responses as described.
1,12
Seizure frequency
Mean and percentage change in monthly motor seizure frequency were calculated for each subject 9 during the 4-week baseline period and over the 12-week observation period following CBD initiation. Responders had ≥50% reduction in mean monthly motor seizures from baseline.
Statistical analysis
Descriptive statistics (Tables 1 and 2 ) were calculated for demographic data, seizure frequency, and QOLCE measurements. Variance was expressed as standard deviation for means and 25-75 percentile interquartile range (IQR) for medians. Baseline and post-CBD treatment (12 weeks) total motor seizure rates were compared using a Wilcoxon rank sum test. Baseline and post-CBD treatment QOLCE values were compared using paired t test for the overall QOL score. Post hoc comparison of individual subscore changes was also performed using paired t test with HolmBonferroni correction for multiple comparisons with a = 0.05. Secondary analyses compared QOLCE score changes between responders (≥50% reduction in total convulsive seizures) and nonresponders to CBD, as well as those patients with and without particular adverse events using a 2 9 2 mixed analysis of variance design (responder or adverse effect [yes vs. no] 9 baseline QOL score vs. post-CBD QOL score). Associations between percentage seizure reduction and overall percentage change in QOLCE scores were assessed via simple linear regression analysis. All analyses were conducted using the Statistical Package for Social Sciences version 22 (IBM SPSS, Armonk, NY, U.S.A.). 
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Results
Sixty subjects enrolled in the EAP at NYU between January 15, 2014 and April 15, 2015. One patient was excluded due to a progressive neurological disorder. Eighty percent of patient caregivers (n = 48) completed both pre-and posttreatment QOLCE surveys and were included in subsequent analysis. Reasons for incomplete forms include: withdrawal of consent (n = 1), subject death from probable sudden unexpected death in epilepsy (n = 1), and failure to return survey form (n = 10). Table 1 provides the baseline characteristics for 48 study subjects. There was no difference in age, number of baseline AEDs, baseline motor seizure frequency (Mann-Whitney U test, p > 0.05), or gender (Fisher's exact test, p = 0.73) between subjects who completed the QOLCE survey and those who did not.
Changes in seizure in frequency
The median baseline monthly motor seizure frequency was 27.5 (IQR = 12.0-89.0), and median baseline monthly total seizure frequency was 33.0 (IQR = 16.4-108.7). The median dose achieved during the titration period was 25 mg/kg (range = 10.2-51). The median monthly motor seizure frequency during the 12-week observation period was 13.9 (IQR = 5.2-46.4), and median percentage change from baseline was À39.4% (IRQ = À69.6 to À12.0%; Z = À3.8, p < 0.001). Twenty subjects (41.7%) were ≥50% responders. There was no significant difference in median percentage change in seizure frequency between the 48 subjects who completed both QOLCE surveys and the 12 who did not (data not shown; Z = À1.2, p = 0.22).
Changes in reported QOLCE
The baseline mean overall QOLCE score was 37.8 AE 7.8. Following 12 weeks of treatment, the mean QOLCE score increased to 45.7 AE 8.5 (t = 5.7, p < 0.001), with a mean change from baseline of 8.1 AE 9.9. Table 2 lists domain-specific QOLCE subscores. Univariate analysis adjusted for multiple comparisons identified statistically significant improvements in energy/fatigue (t = 3.1, unadjusted p = 0.003), memory (t = 7.1, unadjusted p < 0.001), other cognitive functions (t = 4.2, unadjusted p < 0.001), control/helplessness (t = 4.6, unadjusted p < 0.001), social interactions (t = 3.1, unadjusted p = 0.003), behavior (t = 3.4, unadjusted p = 0.001), and QOL item subscores (t = 4.6, p < 0.001) following 12 weeks of CBD.
Relationship of QOLCE changes, seizures, and reported adverse effects
There was no relationship between change in weighted QOLCE and percentage change in monthly motor seizures (b = À0.002, p = 0.9), and overall QOLCE did not differ between ≥50% responders and nonresponders (mean change = 6.6 AE 8.5 vs. 9.0 AE 11.1; F = 0.06, p = 0.802). There was no observed relationship between the number of adverse effects and overall QOLCE score change (b = 0.07, p = 0.671). Patients who experienced somnolence, drowsiness, or fatigue (n = 28 vs. n = 20 without) did not differ in scores of physical restrictions, energy/fatigue, or activity (F = 0.11, p = 0.742; data not shown), nor were there differences in the change in anxiety, depression, or behavior subscores among subjects with psychiatric adverse events (n = 10) compared to those without (n = 38; p > 0.05; data not shown).
Discussion
We observed improvements in caregiver-reported QOL in children and young adults with severe, childhood onset epilepsy in a prospective, open-label study of CBD. Following CBD treatment, caregivers reported significant improvements in multiple QOLCE domains, including energy/fatigue, memory, other cognitive functions, control/ helplessness, social interactions, and behavior, as well as improvements in general QOL subscores. These findings paralleled prior observational studies with medicinal cannabis treatment in treatment-resistant epilepsy populations; parents reported improved mood, alertness, sleep, behavior, and language. 6, 11 It is difficult to discern whether improved QOL results primarily from direct medication effects, reduced seizures, or psychological benefits of reduced seizures, as each factor independently contributes to QOL, but the effects are not easily dissociable. 13 We found no correlation between improvements in QOLCE and adverse events or changes in seizure frequency with CBD, which was surprising given the relationship between seizure frequency, medication side effects, and QOL in epilepsy. 13 Thus, CBD may improve health-related QOL independent from its effects on reducing overall seizure burden. 9 Improvements in sleep, mood, and overall mental health may reflect anxiolytic or other effects of CBD (reviewed in Blessing et al. 14 ). The primary limitations of this study are lack of blinding or comparator group. Conclusions from this study should be interpreted cautiously, because the patients, caregivers, and clinicians were aware they were receiving CBD, increasing the potential for placebo responses seen in retrospective trials with CBD. 6 Furthermore, caregiver-reported QOL measures may partly reflect views of the caregiver rather than patient experiences, prompting future studies measuring the QOL of caregivers alone or patients themselves. Expectations may have been heightened from media coverage, selection to participate, and other clinical trial benefits (Hawthorne effect), potentially biasing parents to reported improvements. A minority of eligible caregivers (17%) did not complete both pre-and post-CBD QOLCE, which may bias our results to positive endorsements of QOL changes. In addition, we did not prospectively track other seizurerelated factors such as duration of seizures or postictal state, and improvements in these factors could also have led to QOL benefits independent of seizure frequency. Finally, repeated exposure to the QOLCE questionnaire may also lead to improved scores independent of treatment effect; however, prior studies using repeated administration of the QOLCE scale in newly treated 15 or surgically treated 12 patients did not demonstrate a significant improvement in the patients who had continued seizures. To rule out a potential CBD-independent practice effect of longitudinal improvement and prevent the aforementioned biases, we encourage future randomized double-blind clinical trials to assess QOL with CBD in specific epilepsy syndromes.
